Related Experiment Video
Updated: Oct 20, 2025

Functional Characterization of Endogenously Expressed Human RYR1 Variants
Published on: June 9, 2021
Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives
Mathilde Beaufils1, Lauriane Travard1, John Rendu1
1Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble,France.
Abstract:
RyR1-related myopathies are a family of genetic neuromuscular diseases due to mutations in the RYR1 gene. No treatment exists for any of these myopathies today, which could change in the coming years with the growing number of studies dedicated to the pre-clinical assessment of various approaches, from pharmacological to gene therapy strategies, using the numerous models developed up to now. In addition, the first clinical trials for these rare diseases have just been completed or are being launched. We review the most recent results obtained for the treatment of RyR1-related myopathies, and, in view of the progress in therapeutic development for other myopathies, we discuss the possible future therapeutic perspectives for RyR1-related myopathies.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Rheumatic Heart Disease III: Medical Management
Satellite Stem Cells and Muscular Dystrophy

